Invasive prenatal (fetal) diagnostic testing may be used to identify pathogenic genetic alterations in fetuses at increased risk based on prenatal screening or in women who choose to undergo diagnostic testing due to other risk factors. This evidence review only addresses the use of chromosomal microarray (CMA) testing, molecular diagnosis of single-gene disorders, and next-generation sequencing.
Localización de Nuestra Oficina principal:
Dirección Física:
1441 F.D. Roosevelt Ave.
San Juan, P.R. 00936
Dirección Postal:
P.O. Box 363628
San Juan, P.R. 00936-3628